© Reuters. Test tubes are seen in front of Seagen logo in this illustration taken June 27, 2022. REUTERS/Dado Ruvic/Illustration/File Photo
BRUSSELS (Reuters) – Pfizer (NYSE:)’s $43 billion bid for Seagen will be decided by EU antitrust regulators by Oct. 19, a regulatory filing showed on Friday.
U.S. pharmaceutical company Pfizer announced the deal, its biggest, in March for Washington-based Seagen, a pioneer of antibody-drug conjugates, which work like “guided missiles” designed to destroy cancer while sparing healthy cells.
The European Commission can either clear the deal after a preliminary review or it can start a four-month long investigation if it has serious concerns.
Pfizer sought EU antitrust approval on Thursday.
Read the full article here
